Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aarti DrugsNSE:AARTIDRUGS -2.00%74 EV-to-EBITDA is 13.28 as of Sep. 08, 2026, which is 6% above its 10-year median of 12.56. GuruFocus rates NSE:AARTIDRUGS with a GF Score™ of 74/100 and a GF Value™ of ₹519.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 726 Drug Manufacturers companies, Aarti Drugs ranks better than 51.1% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aarti Drugs's enterprise value is ₹44,369 Mil.
Aarti Drugs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹3,341 Mil. Therefore, Aarti Drugs's EV-to-EBITDA for today is 13.28.
The historical rank and industry rank for Aarti Drugs's EV-to-EBITDA or its related term are showing as below:
NSE:AARTIDRUGS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.64 Med: 12.56 Max: 23.93
Current: 13.28
During the past 13 years, the highest EV-to-EBITDA of Aarti Drugs was 23.93. The lowest was 4.64. And the median was 12.56.
NSE:AARTIDRUGS's EV-to-EBITDA is ranked better than 51.1% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.75
vs NSE:AARTIDRUGS: 13.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aarti Drugs's PE Ratio (TTM) for today is calculated as:
Aarti Drugs's share price for today is ₹423.00.
Aarti Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹20.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Aarti Drugs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Drugs EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aarti Drugs's EV-to-EBITDA falls into.
Aarti Drugs's current Enterprise Value is ₹44,369 Mil.
Aarti Drugs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,341 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Drugs (NSE:AARTIDRUGS) has a EV-to-EBITDA of 13.28 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aarti Drugs. This is near median its historical median of 12.56. Over the past decade, Aarti Drugs' EV-to-EBITDA has ranged from 4.64 to 23.93. According to the industry distribution chart, Aarti Drugs ranks #355 out of 726 companies in the Drug Manufacturers industry, placing it in the top 48.9%.
Is Aarti Drugs' EV-to-EBITDA too high?
Aarti Drugs' current EV-to-EBITDA of 13.28 is near median its 10-year median of 12.56. Over the past 10 years, this metric has ranged from a low of 4.64 to a high of 23.93. The Drug Manufacturers industry median EV-to-EBITDA is 13.75. Aarti Drugs' value of 13.28 is 3.4% below this industry median. Based on the distribution chart, Aarti Drugs ranks #355 out of 726 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aarti Drugs has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Drugs' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarti Drugs ranks #355 out of 726 companies for EV-to-EBITDA. This puts Aarti Drugs in the upper half of its industry. The industry median EV-to-EBITDA is 13.75. Aarti Drugs' value of 13.28 is 3.4% below this benchmark. Historically, Aarti Drugs' own EV-to-EBITDA has ranged from 4.64 to 23.93 over the past decade. While the company's 10-year median is 12.56 vs. the industry median of 13.75, Aarti Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.75, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Drugs's current EV-to-EBITDA of 13.28 is 3.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aarti Drugs. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Drugs's current EV-to-EBITDA is 13.28, which is near median its own 10-year median of 12.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Drugs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Drugs (NSE:AARTIDRUGS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹519.57, compared to a current price of ₹423.00 — trading 18.6% below its estimated fair value. The current EV-to-EBITDA is 13.28, which is near median its 10-year median of 12.56 and 3.4% below the Drug Manufacturers industry median of 13.75. Aarti Drugs' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aarti Drugs (NSE:AARTIDRUGS), the current EV-to-EBITDA is 13.28 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued.
The current stock price of ₹423.00 is trading 18.6% below its estimated GF Value™ of ₹519.57.
GuruFocus considers Aarti Drugs to be Modestly Undervalued.
Key valuation signals for NSE:AARTIDRUGS:
EV-to-EBITDA: 13.28 (near median its 10-year median of 12.56)
GF Value™: ₹519.57 vs. price of ₹423.00 (18.6% below fair value)
Industry Position: 3.4% below the Drug Manufacturers median (#355 of 726)
No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
74GF Score
Get the complete analysis for NSE:AARTIDRUGS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIDRUGS has been successfully added to your 
